MedTrace Logo

Human Fetal Liver Cell Transplantation in Chronic Liver Failure

NCT01013194 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2015-11-03

Study results available
· View outcomes & findings →

Summary

The herein study consists in the transplantation of liver progenitor cells isolated from human fetal liver tissue with the aim of improving conventional liver therapy and broadening therapeutical options other than liver transplantation.

Conditions

Interventions

OTHER

Human Fetal Liver Cell Transplantation

Human Fetal Liver Cell Transplantation. Cell source: Non-purified and non-selected fetal liver cells from fetuses aborted between the 16th and 26th week of gestation. Infusion technique: Isolation and incannulation of the femoral artery.Splenic artery infusion under radiological guidance. Cell infusion: between 5 and 10x10\^8 cells. Number of sessions: up to 2.

Sponsors & Collaborators

  • University of Pittsburgh

    collaborator OTHER

  • The Mediterranean Institute for Transplantation and Advanced Specialized Therapies

    lead OTHER

Principal Investigators

  • Bruno Gridelli, MD · ISMETT-UPMC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2011-04-30
Completion
2011-07-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01013194 on ClinicalTrials.gov